Preclinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1-translocated lung cancer.
about
Clinical use of crizotinib for the treatment of non-small cell lung cancerCrizotinib: from discovery to accelerated development to front-line treatmentThe Evolution of Therapies in Non-Small Cell Lung CancerTreating patients with ALK-positive non-small cell lung cancer: latest evidence and management strategyTargeted therapies for patients with advanced NSCLC harboring wild-type EGFR: what's new and what's enoughMolecular testing in lung cancer in the era of precision medicineMolecular pathology of non-small cell lung cancer: a practical guide.Crizotinib in ROS1-rearranged non-small-cell lung cancer.Detection of Crizotinib-Sensitive Lung Adenocarcinomas With MET, ALK, and ROS1 Genomic Alterations via Comprehensive Genomic Profiling.Mutant HRAS as novel target for MEK and mTOR inhibitorsSecond- and third-generation ALK inhibitors for non-small cell lung cancerFrom single-gene to multiplex analysis in lung cancer, challenges and accomplishments: a review of a single institution's experience.Epidermal growth factor receptor (EGFR) mutations in lung cancer: preclinical and clinical data.Clinical data from the real world: efficacy of Crizotinib in Chinese patients with advanced ALK-rearranged non-small cell lung cancer and brain metastasesMolecular pathways: ROS1 fusion proteins in cancer.Crizotinib: a review of its use in the treatment of anaplastic lymphoma kinase-positive, advanced non-small cell lung cancer.Activated RET and ROS: two new driver mutations in lung adenocarcinoma.Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases.Identification of Existing Drugs That Effectively Target NTRK1 and ROS1 Rearrangements in Lung Cancer.De novo ALK kinase domain mutations are uncommon in kinase inhibitor-naïve ALK rearranged lung cancers.Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation.Family history of lung cancer in never smokers with non-small-cell lung cancer and its association with tumors harboring EGFR mutations.ROS1 expression in invasive ductal carcinoma of the breast related to proliferation activity.Novel targets in non-small cell lung cancer: ROS1 and RET fusionsKinase inhibitor-responsive genotypes in EGFR mutated lung adenocarcinomas: moving past common point mutations or indels into uncommon kinase domain duplications and rearrangements.Opportunities and challenges in the era of molecularly targeted agents and radiation therapySmoking status and self-reported race affect the frequency of clinically relevant oncogenic alterations in non-small-cell lung cancers at a United States-based academic medical practice.ROS1 immunohistochemistry for detection of ROS1-rearranged lung adenocarcinomas.Dual ALK and EGFR inhibition targets a mechanism of acquired resistance to the tyrosine kinase inhibitor crizotinib in ALK rearranged lung cancer.Rare mutations in non-small-cell lung cancer.Targeted therapy for NSCLC with driver mutations.Molecular targets in the treatment of non-small-cell lung cancer: is there hope on the horizon?Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.ROS1 Fusions Rarely Overlap with Other Oncogenic Drivers in Non-Small Cell Lung Cancer.Crizotinib inhibits migration and expression of ID1 in MET-positive lung cancer cells: implications for MET targeting in oncology.Proteomic profiling identified multiple short-lived members of the central proteome as the direct targets of the addicted oncogenes in cancer cells.Atrial fibrillation was changed into sinus bradycardia in a ROS1-positive advanced lung adenocarcinoma patient who achieved durable response to Crizotinib: A case report and literature review.Target therapy in NSCLC patients: Relevant clinical agents and tumour molecular characterisation.ROS1 mutation and treatment with crizotinib in a 30-year old Caucasian woman with stage IV non-small cell lung cancer/adenocarcinoma and complete remission.Moving more potent and less toxic options to the frontline in the management of advanced lung cancer.
P2860
Q24630466-6ECF5D2D-9F50-4D9A-A7FB-E58322D6B3B5Q26738385-664E9EB4-479F-4A4B-BFF9-E2964ED1D9DCQ26786932-A0955451-D453-4D70-AE62-063E1E136F55Q26795555-F6F26A93-B920-45B4-9ABB-F7C24F8B8FBAQ26799467-59D96822-C66C-4208-A233-E739228FA265Q26824599-69989D78-CB12-49F0-B9C2-A77D104BBE80Q27690919-FD07270E-D034-4BD6-93BB-60E48D9C03C5Q27853075-729E938C-0296-4F65-A825-E63C3C7E4511Q27853157-9ECE6F14-536E-4A1A-A1FF-844D6ED0652CQ27853238-6808ECBE-176F-4327-B624-BFAED8522503Q28072496-5D0A9B7E-0A15-4E58-B107-8C3AFB924EB6Q28385559-5FCF69A7-390F-47A4-92E9-B40F30111E7FQ30850656-5EA55C4A-5F5E-40D2-BE78-4D2F5E2AA4ECQ31141961-E6A29760-BCCD-4A6F-A867-FE891937BC26Q34347504-69B9A9BD-F78F-46BC-BB81-326F263AFE32Q34388696-139C3CDC-7CB9-4776-B232-BBF41F576A25Q35206630-DAC76F65-DB85-4E87-BAC8-2C574B133E66Q35549714-7F179F46-6B61-4B75-8AD8-8418AB1CF062Q36066539-7CBAA14C-5F95-41E7-85CD-87D58CEC07A3Q36114660-E2233246-323E-4EB8-BADE-F9AE6C33CA31Q36493522-D22A63A4-C1FB-43CC-8FC4-B9B01CB8C45AQ36592419-EBC3EEE6-89F5-4AB2-AB0F-B30EE4737764Q36793176-27A8292B-4AE6-4109-AB16-A11F763237D8Q37038500-360FBB7C-135D-4CEA-B80B-104127F71D67Q37060709-7B2C26C0-1EC6-4AAB-B383-9BC607C5530FQ37069689-9898852D-FBC1-46E8-A692-E38CF475A96DQ37238413-FA2CF358-83D7-48EB-ABAE-D5FC999111D4Q37317847-5908A195-8F76-4DE4-AE4F-65225BD4D059Q37626056-478DC42F-B30D-471E-AC39-912749914C14Q38104414-81BC512D-CE3F-4A60-8793-20EB25734539Q38127728-6B6C64D5-8D34-4B10-A8D0-37B4AA3C8663Q38267142-44E913B9-C3E9-4A69-8478-009313B50DABQ38653663-188AFE63-1692-4405-96AE-D38F48277440Q39020417-86E73CFA-9EA5-456F-9DFB-E1EC9C0628DCQ39027803-0F68B47F-F23B-492B-A411-22037E4DDCDAQ39084337-7ECE2736-FA7B-429C-B9E5-9D72DF2A322EQ39326635-18D00227-E5EF-48E5-A8BB-39A014C3DAD5Q42582783-794A6D89-C56D-4C20-AF77-D4C92B489C92Q43101538-7D4B558F-C5A2-4AAF-9D23-28F37AA6F176Q47108604-4847E4CF-AB48-43B7-BC3D-2DD999CF598E
P2860
Preclinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1-translocated lung cancer.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Preclinical rationale for use ...... ROS1-translocated lung cancer.
@ast
Preclinical rationale for use ...... ROS1-translocated lung cancer.
@en
type
label
Preclinical rationale for use ...... ROS1-translocated lung cancer.
@ast
Preclinical rationale for use ...... ROS1-translocated lung cancer.
@en
prefLabel
Preclinical rationale for use ...... ROS1-translocated lung cancer.
@ast
Preclinical rationale for use ...... ROS1-translocated lung cancer.
@en
P2093
P2860
P1476
Preclinical rationale for use ...... ROS1-translocated lung cancer
@en
P2093
Hiroyuki Yasuda
Lorena L de Figueiredo-Pontes
Susumu Kobayashi
P2860
P304
P356
10.1097/JTO.0B013E3182570919
P577
2012-07-01T00:00:00Z